ResistancePlus® GC received clearance from the Australian Therapeutic Goods Administration (TGA) today. Launched in December with CE-IVD mark for sale in Europe, Australian laboratories can now access this world-first diagnostic technology for gonorrhoea.
ResistancePlus® GC detects Neisseria gonorrhoeae and markers associated with susceptibility or resistance to ciprofloxacin. This additional information supports clinicians to preferentially treat with this simple oral antibiotic, preserving last-line ceftriaxone injection treatment.
Dual therapy ceftriaxone and azithromycin was introduced into recommended treatment guidelines for gonorrhoea due to emerging resistance to ciprofloxacin, however up to 70% of Australian infections are still susceptible according to recent surveillance data.
View the clinical information brochure to learn more.